Navigation Links
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
Date:11/26/2008

ibuted to this negative outcome, not only to build upon this insight for our Parkinson's program, but also to help assure continued successful development of our product candidates for other diseases."

About Phase 2 Trial of CERE-120

Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in November 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for 12 months for safety and efficacy.

About CERE-120

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair

damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion. Genzyme Corporation has licensed the ex-North American rights for the development and commercialization of CERE-120 from Ceregene, an agreement that was announced
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Ceregene Announces Two Key Additions to Leadership Team
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... The Latin American hardware encryption display ... America with analysis and forecast of revenue. This market ... expected to reach $2,366.8 million by 2018, at a ... through the TOC of the Latin American hardware encryption ... analysis provided. It also provides a glimpse of the ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
(Date:10/19/2014)... The report "Unmanned Ground Vehicle Market by ... Type & by Geography - Forecasts & Analysis ... vehicle market into various sub segments with an ... report also identifies the factors driving this market, ... the adoption trends. , The unmanned ground vehicle ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5
... Stock Exchange Symbol: MS, EDMONTON, Sept. 4 ... developer in the treatment of multiple sclerosis (MS), ... of the United States,has granted fast track designation ... treatment of secondary progressive MS (SPMS). Dirucotide,(MBP8298) is ...
... Out-License Intellectual ... ... ILI ), and Access Business Group International LLC, a division,of Alticor ... property related to genetic tests jointly developed by,Interleukin Genetics and Access ...
... cities -- urban leaders and globalisation experts -- will ... landmark conference, Futuropolis 2058. , They will share ... that will affect cities in the future. ... theory, Michio Kaku, Ph.D., is the keynote speaker, addressing ...
Cached Biology Technology:BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests 2Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests 3Singapore to hold international 'pow-wow' 2Singapore to hold international 'pow-wow' 3
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/16/2014)... Post-menopausal women experienced improvements in vaginal atrophy, with ... bleeding, after 12 weeks of daily 10 milligram ... nutritional supplement previously shown to help relieve certain ... study reported in a poster at the North ... , "These data documented improved vaginal epithelium, without ...
(Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... water loss is an important ability for modern land plants ... research from the University of Bristol, published today in the ... occurred very early in plants, evolutionary history. The research ... surface of leaves that allow carbon dioxide gas to be ...
... Given how much patients invest in in vitro fertilization (IVF), ... they might expect during their treatment can be welcome. A ... Hospital shows that as the IVF cycle is beginning, a ... antimullerian hormone, can help predict the number of eggs that ...
... in addition to being the source of many economically ... millions of people daily. Striking morphological and ecological variability ... than 2,400 species, and has inspired almost two centuries ... less compelling, is the internal structure of palmsan understanding ...
Cached Biology News:Adjustable valves gave ancient plants the edge 2Hormone test helps predict success in IVF 2